Invitrogen, Procter & Gamble Extend Research Agreement
News Nov 02, 2005
Invitrogen Corporation has announced the extension of an RNAi research service agreement with Procter & Gamble Pharmaceuticals, Inc. (P&GP). The research service agreement is now in its fourth year and will continue through December 2006.
Through use of Invitrogen's RNAi expertise and proprietary technologies, the research service collaboration facilitates P&GP's target identification and validation programs.
Since the inception of the service agreement, Invitrogen has continually broadened the research collaboration through the use of a variety of proprietary technologies including Stealth™ RNAi, Gateway® and lentiviral vectors.
"The success and extension of this research service agreement is a testament to the value that Invitrogen's services have brought to P&GP's target identification and validation programs," said Gregory T. Lucier, Chairman and CEO of Invitrogen.
"As Invitrogen continues to grow and expand our research technology and service portfolio, partnerships like this will allow us to significantly impact vital work in disease research and ultimately enhance more lives."
"Invitrogen's suite of RNAi technologies help to make our drug discovery research more efficient, and increase our understanding of disease mechanisms," said Ray Takigiku, PhD, Director of Core Technologies, Procter and Gamble Pharmaceuticals.
4000-Year Old DNA Helps Track the Spread of Rice Farming in AsiaNews
Rice farming spread far and wide in ancient Southeast Asia, but how it got there has been a mystery. Now, a study of 4000-year-old DNA—a rare find in this region—suggests it came with farmers migrating from China, where rice farming originated.
Island Life: Worm-eating Mice Hold Clues to EvolutionNews
How much space does a population need to branch out and form a new species? A small island in the Philippines, and four species of mice that live on it, have helped researchers work out the answer.READ MORE
Gonorrhoea Genome Maps Out STD Across EuropeNews
The first European-wide genomic survey of gonorrhoea has mapped antibiotic resistance in this sexually transmitted disease throughout the continent. Researchers also showed that using DNA sequencing data they could accurately determine antibiotic resistance and identify incorrect laboratory test results.
Comments | 0 ADD COMMENT
Epigenetics in the nervous system: development and disease
Oct 01 - Oct 03, 2018